Segment Reporting - Segment information (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025
Segment Reporting
Grant and award revenue	$ 789	$ 491
Total research and development expenses	6,111	5,429
Total general and administrative expenses	3,463	3,253
Impairment expense			$ 5,400
Total operating expenses	9,574	8,682
Operating loss	(8,785)	(8,191)
Other income (expense), net	(106,561)	1,660
Net loss	(115,346)	(6,531)
Single Reportable Segment
Segment Reporting
Grant and award revenue	789	491
Expenses not allocated by projects	894	520
Total external research and development expenses	983	744
Research and development personnel expenses	2,625	2,313
Other research and development expenses	2,503	2,372
Total research and development expenses	6,111	5,429
General and administrative personnel expenses	1,462	1,401
Other general and administrative expenses	2,001	1,852
Total general and administrative expenses	3,463	3,253
Total operating expenses	9,574	8,682
Operating loss	(8,785)	(8,191)
Other income (expense), net	(106,561)	1,660
Net loss	(115,346)	(6,531)
Single Reportable Segment | AP-PA02: Non-Cystic Fibrosis Bronchiectasis
Segment Reporting
External research and development expenses	(26)	(440)
Single Reportable Segment | AP-PA02: Cystic Fibrosis
Segment Reporting
External research and development expenses		11
Single Reportable Segment | AP-SA02: Bacteremia
Segment Reporting
External research and development expenses	$ 115	652
Single Reportable Segment | AP-SA02: Prosthetic Joint Infection
Segment Reporting
External research and development expenses		$ 1